Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Nov;56(5):360-6.
doi: 10.1016/j.phrs.2007.09.003. Epub 2007 Sep 11.

Enhancement of Endocannabinoid Signaling and the Pharmacotherapy of Depression

Affiliations
Free PMC article
Review

Enhancement of Endocannabinoid Signaling and the Pharmacotherapy of Depression

Regina A Mangieri et al. Pharmacol Res. .
Free PMC article

Abstract

Cannabinoids are well known modulators of mood and emotional behavior. Current research supports a role for endocannabinoid signaling in the treatment of depression. Changes in levels of the cannabinoid CB(1) receptor or the endogenous CB(1) receptor ligands, anandamide and 2-AG, are observed both in humans suffering from depression and in animal models of depression, and experimental manipulation of CB(1) receptor signaling has also been shown to affect emotional reactivity in rodents. Importantly, inhibitors of anandamide inactivation have demonstrated efficacy in enhancing stress-coping and mood-related behavior. This article will review these areas of research, highlighting the potential of endocannabinoid metabolism modulators as therapeutics for the treatment of depression.

Similar articles

See all similar articles

Cited by 22 articles

See all "Cited by" articles

Publication types

Feedback